Press Releases - OXB

Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More

Oxford Biomedica signs new three year agreement with AstraZeneca

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More

Oxford Biomedica notes announcement that FDA has lifted clinical hold on Homology Medicines’ pheNIX trial

Oxford, UK – 14 June 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the recent announcement from Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company regarding the pheNIX gene therapy trial. The U.S. Food and Drug Administration (FDA)… Read More

Oxford Biomedica Solutions announces novel Dual Plasmid Transfection System, and has demonstrated suspension bioreactor titres above E15 vg/L, and chromatography purification achieving 90% fully in-tact vector

Bedford, Massachusetts – May 6, 2022: Oxford Biomedica Solutions, LLC. (“Oxford Biomedica Solutions”), a new high-performing, full scope AAV manufacturing and innovation business, now offering its ‘Plug & Play’ Platform that has successfully delivered four GMP programs and five Investigational New Drug submissions. Oxford Biomedica Solutions is announcing today that… Read More

2021 Annual report and accounts & AGM notification

London, UK – 27 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a leading gene and cell therapy group, gives notice that copies of the 2021 Annual report and accounts and the… Read More

Preliminary results for the year ended 31 December 2021

Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I… Read More

Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director

Oxford, UK – 13 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, announces the appointment of Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect. Ms. Patel has extensive international experience in manufacturing and end… Read More

Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology

Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, is pleased to announce that it has completed… Read More

Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease

This is a partner product. Visit the relevant partner website for further information. Read More

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner

Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new US-based AAV manufacturing and innovation business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programmes and genetic medicines platform Oxford Biomedica to invest $50 million to fund… Read More

John Dawson to retire from Oxford Biomedica

Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the… Read More

Oxford Biomedica Signs Licence and Supply Agreement with Cabaletta Bio for LentiVector® Platform

Oxford, UK – 5 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia, USA-based clinical-stage biotechnology company focused… Read More